IA
CLSD

IFP Advisors’s Clearside Biomedical CLSD Stock Holding History

IFP Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-273
Closed -$4K – 2524
2018
Q4 		$4K Buy
273
+133
+95% +$6.24K ﹤0.01% 2916
2018
Q3 		$13K Buy
140
+100
+250% +$11.9K ﹤0.01% 2690
2018
Q2 		$6K Buy
+40
New +$6.74K ﹤0.01% 3148

Other funds holding CLSD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

IFP Advisors's CLSD Position: Q1 2019 in Review

IFP Advisors sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 273 shares — an estimated $4K sold.

IFP Advisors first reported a position in CLSD in Q2 2018 and held it in 3 quarters. The position peaked at $13K in Q3 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

  • IFP Advisors reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
  • IFP Advisors sold 273 Clearside Biomedical shares in Q1 2019, an estimated $4K.
  • IFP Advisors first reported a position in Clearside Biomedical in Q2 2018 and held it in 3 quarters.
  • IFP Advisors's Clearside Biomedical position peaked at $13K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.